Objective. To observe the therapeutic effect and the incidence of adverse reactions of total body irradiation plus cyclophosphamide (TBI/CY) and busulfan plus cyclophosphamide (BU/CY) in the treatment of pediatric hematopoietic stem cell transplantation. Methods. By searching the Cochrane Library, PubMed, Web of Knowledge, Embase, Chinese Biomedical Literature Database (CBM), and screening randomized controlled trials (RCTs), quality evaluation and data extraction were performed for the included literature, and meta-analysis was performed for RCTs included at using Review Manager 5.2 software. Results. A total of 10160 patients were enrolled in 15 RCTs, including 5211 patients in the TBI/CY group and 4949 patients in the BU/CY group. Meta-analysis showed that there was a statistical difference in transplant failure rate (OR = 1.56, 95% CI (1.23, 1.97), P = 0.0002, I2 = 56%, Z = 3.69), transplant mortality (OR = 1.45, 95% CI (1.24, 1.68), P < 0.00001, I2 = 76%, Z = 4.80), transplantation long-term disease-free survival rate (OR = 1.52, 95% CI (1.09, 2.12), P = 0.01, I2 = 0%, Z = 2.50), and transplantation adverse reactions (OR = 1.28, 95% CI (1.08, 1.52), P = 0.004, I2 = 0%, Z = 2.85). Conclusion. Meta-analysis showed that TBI/CY combined pretreatment regimen was more effective than BU/CY regimen alone in the treatment of pediatric hematologic transplantation, with a lower incidence of adverse reactions and significant long-term survival efficacy.

Background. Overweight and obesity have been reported in specific patients and disease survivors compared to other types of childhood cancer. This study is aimed at determining the effect of children’s obesity on the mortality of acute lymphoblastic leukemia. Method. Children admitted to Inner Mongolia International Mongolian Hospital from 1 January 2017 to 31 December 2020 participated in this study. 1070 children were analyzed. A multi-middle-class poll was conducted. All children under the age of 15 were followed up within 24 months of diagnosis. Overweight and obesity are identified according to the World Health Organization and the Centers for Disease Control and Prevention. Premature death and reoccurrence of emergencies are the main consequences. Results. The initial ethical rate for the first 24 months of testing was 19.9% (NS 213). The lowest cancer survival rate (DFS) was childhood obesity (73%) (24 months), compared with average weight (81%). Diagnosis of overweight/obesity is a predictor of early death (WHO: HR = 1.4 , 95% CI: 1.0-2.0; CDC: HR = 1.6 , 95% CI: 1.1-2.3). However, there was no association between overweight and obesity (WHO: HR = 1.5 , 95% effective interval: 0.9-2.5; CDC: human   resources = 1.0 , 95% effective interval: 0.6-1.6) and obesity (WHO: HR = 1.5 , 95% effective interval: 0.7-3.2; CDC: HR = 1.4 , 95% effective interval: 0.9-2.3). Early recurrence was observed. Conclusion. Overweight and obese people belong to the subclass with a high risk of death in the treatment of leukemia.